The ABCC1 Knockout SK-HEP-1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human SK-HEP-1 hepatic adenocarcinoma cell line, engineered to disrupt expression of the ABCC1 gene. This polyclonal format provides a heterogeneous pool of edited cells, eliminating the need for clonal selection and enabling robust functional studies without potential artifacts from single-cell cloning. The knockout model ablates the gene encoding multidrug resistance-associated protein 1 (MRP1), an ATP-binding cassette (ABC) transporter critical for cellular efflux of diverse substrates. By targeting ABCC1, this product offers researchers a powerful tool to dissect MRP1-mediated transport mechanisms in a liver cancer context.
The host SK-HEP-1 cell line was originally isolated from the ascitic fluid of a patient with liver adenocarcinoma and is widely employed as a model for hepatic sinusoidal endothelial cells and liver cancer biology. These cells exhibit characteristic features relevant to hepatocarcinogenesis and drug resistance, including the expression of various uptake and efflux transporters. Their endothelial-like properties and tumor origin make SK-HEP-1 particularly suited for investigating ABC transporter function in the liver microenvironment and for evaluating how drug resistance pathways intersect with hepatic detoxification systems. The combination of this well-characterized host line with targeted ABCC1 disruption provides a physiologically relevant platform for studying MRP1 biology.
MRP1, encoded by ABCC1, functions as an ATP-dependent efflux pump that transports a broad range of substrates, including glutathione S-conjugates, glucuronides, sulfate conjugates, and unmodified chemotherapeutic agents such as doxorubicin and methotrexate. Its activity is tightly regulated by the NRF2 (NFE2L2) transcription factor in response to oxidative stress, as well as by PI3K/AKT, MAPK, NF-??B, and AP-1 signaling pathways. Upon activation, MRP1 exports molecules like leukotriene C4 (LTC4) and cyclic AMP, while also modulating intracellular glutathione levels and redox balance. The transporter physically interacts with ATP for energy, glutathione as a co-substrate, and cytoskeletal ERM (ezrin/radixin/moesin) proteins and PDZ domain-containing proteins for proper membrane localization and function. Disruption of ABCC1 therefore abolishes MRP1-mediated drug efflux, causing intracellular accumulation of toxic chemotherapeutic substrates and glutathione conjugates, which sensitizes cells to drug-induced cytotoxicity and perturbs glutathione-dependent detoxification and inflammatory signaling.
In the SK-HEP-1 hepatic adenocarcinoma model, ABCC1 knockout holds significant relevance for understanding multidrug resistance in liver cancer. Hepatic tumors frequently upregulate MRP1 and other ABC transporters to evade chemotherapy, and SK-HEP-1 cells retain many drug resistance pathways. By eliminating MRP1 efflux activity, this knockout model enables direct assessment of the transporter’s contribution to reduced intracellular drug concentrations and altered redox homeostasis. It allows researchers to dissect how MRP1 collaborates with other resistance factors such as ABCB1 (P-glycoprotein) and ABCG2 (BCRP), and to explore its role in the sinusoidal endothelial cell context, where leukotriene transport and detoxification are particularly relevant. The model thus serves as a critical tool for examining the intersection of drug resistance, oxidative stress responses, and hepatic transport physiology.
Research applications of the ABCC1 Knockout SK-HEP-1 Polyclonal Cells are extensive and include functional characterization of MRP1-dependent transport using calcein-AM efflux assays, cytotoxicity profiling with doxorubicin or methotrexate via MTS/MTT assays, and intracellular drug accumulation measurements by HPLC. The polyclonal population is suitable for western blotting and RT-qPCR to verify ABCC1 ablation and to study compensatory regulation of other transporters. Additional uses encompass screening for novel MRP1 inhibitors, investigating glutathione-dependent detoxification pathways through intracellular GSH quantification, and evaluating the role of MRP1 in LTC4-mediated inflammation within hepatic sinusoidal models. These applications collectively support advanced research into multidrug resistance mechanisms and the development of strategies to overcome chemotherapy failure in liver cancer. For further technical information or to discuss custom applications, please contact Ascent Research.
